FREMONT, Calif., Aug. 1, 2018 /PRNewswire/ -- Ardelyx, Inc.
(NASDAQ: ARDX) today announced that it plans to report its second
quarter 2018 financial results after market close on Tuesday, August 7, 2018. Management will host a
conference call and webcast that afternoon at 4:30 p.m. ET to discuss the results and other
business updates.
To participate in the conference call, please dial (855)
296-9612 (toll-free) or (920) 663-6277 (toll) and reference call ID
number 1592643. A webcast of the call can be accessed by visiting
the Investor section of the Ardelyx website at ir.ardelyx.com. A
replay of the webcast will be available on the Ardelyx website for
60 days following the call.
About Ardelyx, Inc.
Ardelyx is focused on
enhancing the way people with renal diseases are treated by
developing first-in-class medicines. Ardelyx's renal
pipeline includes the Phase 3 development of tenapanor for the
treatment of hyperphosphatemia in people with end-stage renal
disease who are on dialysis and RDX013, a potassium secretagogue
program for the potential treatment of high potassium, or
hyperkalemia, a problem among certain patients with kidney and/or
heart disease. In addition, Ardelyx has completed Phase 3
development of tenapanor for the treatment of irritable bowel
syndrome with constipation and anticipates submitting a New Drug
Application to the U.S. Food and Drug Administration for
this indication in the second half of 2018. To efficiently bring
its treatments to market, Ardelyx is pursuing strategic
collaborations in the U.S. and outside the U.S., with established
agreements with Kyowa Hakko Kirin in Japan, Fosun
Pharma in China and Knight
Therapeutics in Canada. For more information, please
visit http://www.ardelyx.com/ and connect with us on
Twitter @Ardelyx.
View original content with
multimedia:http://www.prnewswire.com/news-releases/ardelyx-announces-date-of-second-quarter-2018-financial-results-and-conference-call-300689712.html
SOURCE Ardelyx